Glucosamine sulphate: an umbrella review of health outcomes.

Abstract

BACKGROUND AND AIMS:

Glucosamine sulphate (GS) can be used as background therapy in people affected by knee osteoarthritis (OA). Knowledge regarding the efficacy and safety of GS is of importance since its use worldwide is increasing. Therefore, the present study aimed to map and grade the diverse health outcomes associated with GS using an umbrella review approach.

METHODS:

Medline, Cinahl and Embase databases were searched until 1 April 2020. An umbrella review of systematic reviews and meta-analyses of randomized controlled trials (RCTs) was carried out. The evidence from the RCTs was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool.

RESULTS:

From 140 articles returned, 11 systematic reviews, for a total of 21 outcomes (37 RCTs; 3949 participants; almost all using 1500 mg/day), were included. No systematic reviews/meta-analyses of observational studies were included. Regarding the findings of the meta-analyses, 9/17 outcomes were statistically significant, indicating that GS is more effective than placebo. A high certainty of evidence, as assessed by GRADE, supported the use of GS (versus placebo) in improving the Lequesne Index, joint space width change, joint space width change after 3 years of follow up, joint space narrowing and OA progression. No difference in terms of adverse effects was found between GS and placebo. In systematic reviews, GS was associated with a better glucose profile and a better physical function performance than placebo.

CONCLUSION:

GS, when used as a prescription drug (i.e. crystalline glucosamine sulphate) at 1500 mg daily dosage, can positively affect the cartilage structure, reduce pain, improve function and glucose metabolism in people with knee OA, without having a greater incidence of adverse effects than placebo.

• Authors: Nicola Veronese, Jacopo Demurtas, Lee Smith, Jean-Yves Reginster, Olivier Bruyère, Charlotte Beaudart, Germain Honvo, Stefania Maggi, on behalf on the European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and Meta-Analyses and Arthritis
• Journal: Therapeutic advances in musculoskeletal disease (Ther Adv Musculoskelet Dis) Vol. 12 Pg. 1759720X20975927 ( 2020) ISSN: 1759-720X [Print] England
• PMID: 33488785 (Publication Type: Journal Article)
• Copyright: © The Author(s), 2020.